Business Wire

As Digital Transformation Accelerates, Entrust Datacard Becomes “Entrust”

14.9.2020 16:27:00 EEST | Business Wire | Press release

Share

Entrust Datacard today announced a new brand identity and company name – Entrust. The move both continues the company’s enduring leadership and innovation in identity, payments, and data protection, and highlights Entrust’s position as a leader in developing the core technologies needed to keep the world moving safely.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005558/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Entrust keeps the world moving safely by enabling trusted identities, payments and data protection. (Photo: Business Wire)

“The global impact of the COVID-19 pandemic has shown us how critical digital transformation is in our daily lives,” said Todd Wilkinson, CEO of Entrust. “As consumers, we depend on digital technologies and security to do more than ever, whether it’s making purchases, crossing borders, accessing government services or logging into corporate networks. We are proud that some of the world’s largest governments, organizations and enterprises trust us to keep citizens, commerce and information moving safely. Making Entrust the foundation of our brand reflects how our technology and innovation are central to securing this ever-evolving world.”

The company was founded as Datacard Corporation in 1969, and acquired Entrust in 2013, becoming Entrust Datacard. Entrust today offers an unmatched breadth of solutions, including credential issuance, identity and data protection, and digital certificates and signing solutions.

Commitment to innovation and growth

In recent years, Entrust has expanded from its core physical credential issuance focus to build a robust digital security solution portfolio and market presence. In addition to a sustained long-term investment in R&D, the company has made a recent series of strategic acquisitions, including PKI providers Trustis and Safelayer, authentication provider SMS Passcode, and nCipher, the market leader in hardware security modules (HSMs).

As a result, Entrust has transformed into one of the world’s largest providers of digital security software, and the global leader in credential issuance solutions. The company is in a unique position to innovate and invest to meet the rising security and identity needs of its customers. Entrust is making significant R&D investments to bring to market new card issuance technology, secure cloud enablement and advancements to its authentication, digital signing, identity management and HSM solutions. The company recently launched its next-generation PKI platform, tailored to meet today’s rising “encrypt everything” demands amidst rising threats, and earlier this year introduced new solutions for passwordless authentication and digital onboarding.

With nearly $800M in annual revenue and 2,500 employees, Entrust is trusted by some of the world’s most demanding, compliance-driven institutions in finance, technology and government. The company provides sales and service in more than 150 countries through 50 offices and a global network of more than 1,000 technology and channel partners.

“Earning the benefits of digital transformation requires a foundation of trust. As identity, payment and data protection ecosystems become more complex and interconnected, trust enables the resiliency and scale needed to make our digital lives possible,” said Frank Dickson, Program VP, Cybersecurity Products, IDC. “Entrust began delivering trust in payment card solutions 50 years ago and has added breadth and depth to its trusted identity and data security solutions ever since. Thus, centering the brand on Entrust makes sense – it helps the market see the common thread of high-assurance trust-building technology that carries through all of its identity, payment and data protection solutions.”

A simplified, refreshed brand

Entrust’s new name and branding honors the company’s heritage as it looks ahead. Datacard will continue to be featured prominently as the product line name for the company’s high-volume card issuance solutions, and the company continues to invest and innovate in high-volume hardware, software, services and supplies. Similarly, while the nCipher name will transition to Entrust over time, the nShield product line name for its market-leading HSMs will be retained and become an Entrust product line.

The branding evolution includes a new logo, brand colors, website, tagline, and positioning that are tightly linked to Entrust’s focus on securing a rapidly changing world.

“In evolving our brand, we wanted to make our mission clear. We come to work every day with one thing in mind: delivering solutions that enable the highest level of trust in every interaction our customers facilitate. Enabling trust is our mission, our value proposition, and the focus of all the innovative technologies we continue to develop for clients worldwide,” said Karen Kaukol, Chief Marketing Officer, Entrust.

To explore the new brand and learn more about Entrust’s products and services, visit www.entrust.com.

About Entrust

Entrust keeps the world moving safely by enabling trusted identities, payments and data protection. Today more than ever, people demand seamless, secure experiences, whether they’re crossing borders, making a purchase, accessing e-government services or logging into corporate networks. Entrust offers an unmatched breadth of digital security and credential issuance solutions at the very heart of all these interactions. With more than 2,500 colleagues, a network of global partners, and customers in over 150 countries, it’s no wonder the world’s most entrusted organizations trust us.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Ken Kadet
Vice President, Public Relations
+1 952.988.1154
ken.kadet@entrustdatacard.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye